ACER — Acer Therapeutics Balance Sheet
0.000.00%
- $19.68m
- $50.19m
Annual balance sheet for Acer Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 41.7 | 12.1 | 5.76 | 12.7 | 2.33 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | — | 5 | 0 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 42.7 | 12.9 | 6.44 | 28.1 | 3.52 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.131 | 0.794 | 0.53 | 0.114 | 0.415 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 50.7 | 21.5 | 14.6 | 36.3 | 11.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5.58 | 2.77 | 6.15 | 29.1 | 19 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 5.58 | 3.1 | 6.39 | 38 | 28.4 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 45.1 | 18.4 | 8.22 | -1.72 | -16.8 |
Total Liabilities & Shareholders' Equity | 50.7 | 21.5 | 14.6 | 36.3 | 11.6 |
Total Common Shares Outstanding |